Samer K. Khaled

Hematology

1400 S Orange Ave
Orlando, FL 32806

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.

Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.

Journal: Haematologica

Published: June 24, 2026

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.

Journal: American journal of hematology

Published: May 29, 2026

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

Journal: Blood advances

Published: May 01, 2026

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

Journal: Blood advances

Published: May 01, 2026

Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.

Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.

Journal: Leukemia

Published: May 05, 2025

Correction: TET2 deficiency promotes MDS-associated leukemogenesis.

Correction: TET2 deficiency promotes MDS-associated leukemogenesis.

Journal: Blood cancer journal

Published: November 28, 2023

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia.

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: April 28, 2023

Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data.

Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data.

Journal: American journal of hematology

Published: April 04, 2023

TET2 deficiency promotes MDS-associated leukemogenesis.

TET2 deficiency promotes MDS-associated leukemogenesis.

Journal: Blood cancer journal

Published: July 07, 2022

Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.

Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 27, 2022

A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.

A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: May 02, 2022

Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.

Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 19, 2022

Showing 1-12 of 56

Last Updated: 09/26/2026